Literature DB >> 8454609

Interaction of ADP-ribosylation factor with Escherichia coli enterotoxin that contains an inactivating lysine 112 substitution.

J Moss1, S J Stanley, M Vaughan, T Tsuji.   

Abstract

Cholera toxin and Escherichia coli heat-labile enterotoxin (LT) exert their effects on cells through ADP-ribosylation of guanine nucleotide-binding proteins. Both toxins consist of one A subunit, which is an ADP-ribosyltransferase, and five B (or binding) subunits. Their enzymatic activities are latent; activation requires reduction and proteolysis, resulting in a catalytically active A1 protein and a much smaller A2 protein. These ADP-ribosyltransferases are activated by GTP-dependent 20-kDa ADP-ribosylation factors or ARFs. To determine if proteolysis plus reduction is required for appearance of the ARF allosteric site as well as for catalytic activity, an inactive mutant of LT, LT(E112K), with replacement of glutamate by lysine at position 112 of its A subunit, was utilized as a competitor in cholera toxin ADP-ribosyltransferase assays containing limiting amounts of ARF. LT(E112K) required trypsinization and reduction to become a potent, concentration-dependent inhibitor. Inhibition was reversed by increasing concentrations of ARF. Reduction or trypsinization alone did not generate an inhibitory form of LT(E112K). These studies are consistent with the conclusion that the ARF site is not expressed in the latent toxin. Both trypsinization and reduction are required for expression of a functional ARF binding site as well as for catalytic activity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8454609

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Mutants of the Escherichia coli heat-labile enterotoxin with reduced ADP-ribosylation activity or no activity retain the immunogenic properties of the native holotoxin.

Authors:  L de Haan; W R Verweij; I K Feil; T H Lijnema; W G Hol; E Agsteribbe; J Wilschut
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

2.  Identification of motifs in cholera toxin A1 polypeptide that are required for its interaction with human ADP-ribosylation factor 6 in a bacterial two-hybrid system.

Authors:  M G Jobling; R K Holmes
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

3.  Common structure of the catalytic sites of mammalian and bacterial toxin ADP-ribosyltransferases.

Authors:  I J Okazaki; J Moss
Journal:  Mol Cell Biochem       Date:  1994-09       Impact factor: 3.396

4.  Construction and characterization of recombinant Vibrio cholerae strains producing inactive cholera toxin analogs.

Authors:  C C Häse; L S Thai; M Boesman-Finkelstein; V L Mar; W N Burnette; H R Kaslow; L A Stevens; J Moss; R A Finkelstein
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

5.  Relationship between a low toxicity of the mutant A subunit of enterotoxigenic Escherichia coli enterotoxin and its strong adjuvant action.

Authors:  T Tsuji; T Yokochi; H Kamiya; Y Kawamoto; A Miyama; Y Asano
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

Review 6.  Host-Microbe-Pathogen Interactions: A Review of Vibrio cholerae Pathogenesis in Drosophila.

Authors:  Saeideh Davoodi; Edan Foley
Journal:  Front Immunol       Date:  2020-01-24       Impact factor: 7.561

7.  Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity.

Authors:  B L Dickinson; J D Clements
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

Review 8.  Protein crystallography and infectious diseases.

Authors:  C L Verlinde; E A Merritt; F Van den Akker; H Kim; I Feil; L F Delboni; S C Mande; S Sarfaty; P H Petra; W G Hol
Journal:  Protein Sci       Date:  1994-10       Impact factor: 6.725

9.  Effects of site-directed mutagenesis of Escherichia coli heat-labile enterotoxin on ADP-ribosyltransferase activity and interaction with ADP-ribosylation factors.

Authors:  L A Stevens; J Moss; M Vaughan; M Pizza; R Rappuoli
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.